Zai Lab ZLAB
NASDAQ ZLAB
$26.23 -0.77 (-2.85%)
As of: Sep 4, 2026 · 3:59 PM EDT

Zai Lab (ZLAB) Liabilities and Shareholders Equity (2016 - 2026)

Zai Lab (ZLAB) posted Liabilities and Shareholders Equity of $1.1 billion for Q1 2026, down 6.54% sequentially from $1.2 billion in Q4 2025, and down 6.61% YoY from $1.2 billion in Q1 2025.

Analysis

Zai Lab (ZLAB) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends

Zai Lab has reported Liabilities and Shareholders Equity for 11 years, with the latest figure at $1.1 billion in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 6.61% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 5.99% YoY) and the FY2025 annual result came in at $1.2 billion, down 1.13% from the prior year.
  • Liabilities and Shareholders Equity eased to $1.1 billion in Q1 2026 per ZLAB's latest filing, from $1.2 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $1.5 billion in Q1 2022 and troughed at $985.3 million in Q3 2024.
  • A 5-year average of $1.2 billion and a median of $1.2 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
  • The widest YoY moves for Liabilities and Shareholders Equity: up 32.67% in 2022, down 25.14% in 2022.
  • Over 5 years, Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then retreated by 15.07% to $1.0 billion in 2023, then increased by 14.42% to $1.2 billion in 2024, then declined by 1.13% to $1.2 billion in 2025, then slipped by 6.54% to $1.1 billion in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.1 billion, $1.2 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 10.96 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.32 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 9.18 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.56 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.10 Bn
10 Zai Lab 2.94 Bn 2.23 Bn 58.15 Mn 1.07 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.07 Bn
Mar 31, 2026 1.10 Bn
Dec 31, 2025 1.17 Bn
Sep 30, 2025 1.16 Bn
Jun 30, 2025 1.16 Bn
Mar 31, 2025 1.17 Bn
Dec 31, 2024 1.19 Bn
Sep 30, 2024 985.35 Mn
Jun 30, 2024 987.37 Mn
Mar 31, 2024 988.44 Mn
Dec 31, 2023 1.04 Bn
Sep 30, 2023 1.04 Bn
Jun 30, 2023 1.11 Bn
Mar 31, 2023 1.17 Bn
Dec 31, 2022 1.22 Bn
Sep 30, 2022 1.30 Bn
Jun 30, 2022 1.42 Bn
Mar 31, 2022 1.50 Bn
Dec 31, 2021 1.61 Bn
Sep 30, 2021 1.73 Bn